Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) (NCT02899052)

🧪 Interventions in This Study

• Carfilzomib (DRUG)
• Venetoclax (DRUG)
• Dexamethasone (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (32 Sites)

Showing the first 25 of 32 sites.

• University of Alabama at Birmingham - Main /ID# 151405 — Birmingham, Alabama
• University of Arkansas for Medical Sciences /ID# 151399 — Little Rock, Arkansas
• Memorial Healthcare System /ID# 224862 — Hollywood, Florida
• Winship Cancer Institute of Emory University /ID# 161710 — Atlanta, Georgia
• The University of Chicago Medical Center /ID# 151395 — Chicago, Illinois
• Indiana Blood & Marrow Transpl /ID# 218862 — Indianapolis, Indiana
• Duplicate_University of Kentucky Chandler Medical Center /ID# 151407 — Lexington, Kentucky
• Central Maine Medical Center /ID# 218856 — Lewiston, Maine
• Duplicate_University of Maryland School of Medicine /ID# 159721 — Baltimore, Maryland
• Oncology Hematology Associates (OHA) - Springfield /ID# 218855 — Springfield, Missouri
• Washington University-School of Medicine /ID# 222651 — St Louis, Missouri
• Duke Cancer Center /ID# 162062 — Durham, North Carolina
• University of Pennsylvania /ID# 151768 — Philadelphia, Pennsylvania
• University of Texas Southwestern Medical Center /ID# 218336 — Dallas, Texas
• Baylor Scott & White Medical Center- Temple /ID# 218252 — Temple, Texas
• University of Utah /ID# 151397 — Salt Lake City, Utah
• Duplicate_VA Puget Sound Healthcare Syst /ID# 155369 — Seattle, Washington
• Aurora Health Care, Aurora Cancer Center /ID# 209612 — Wauwatosa, Wisconsin
• Border Medical Oncology Research Unit Albury Wodonga Regiona /ID# 222200 — East Albury, New South Wales
• Calvary Mater Newcastle /ID# 218739 — Waratah, New South Wales
• Flinders Medical Centre /ID# 221345 — Bedford Park, South Australia
• Royal Hobart Hospital /ID# 217546 — Hobart, Tasmania
• Debreceni Egyetem-Klinikai Kozpont /ID# 217624 — Debrecen, Hajdú-Bihar
• Semmelweis Egyetem /ID# 217626 — Budapest,
• Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 217625 — Budapest,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.